Our Board and Management Team

Steve Carchedi

Steve Carchedi

Chief Executive Officer & Chairman of the Board

Steve is CEO and a Director of Oncology Venture A/S since September 2019. He brings more than 30 years of commercial industry experience focused in oncology from several leading multinational pharmaceutical biotech companies. Steve has served in CEO positions in both privately owned and Nasdaq listed biotech-companies, all with a late stage oncology focus in which he has led financing, commercialization and re-structuring activities.

He was previously President & Chief Executive Officer of Apexian Pharmaceuticals, an early stage oncology discovery and development company focused in novel targets to treat cancer, and earlier served as Chief Executive Officer of Raphael Pharmaceuticals (formerly Cornerstone Pharmaceuticals), an oncology company focused in cancer metabolism.

Earlier in his career, Steve served as the Senior Vice President and President, Commercial Operations (North America) for Mallinckrodt Pharmaceuticals leading the company listing on NYSE. In addition, he previously held senior leadership positions at General Electric, Johnson & Johnson, Eli Lilly & Company and Bristol Myers Squibb. In addition to his executive experience, Steve currently serves on the Board of Directors of Sunesis Pharmaceuticals and Bionumerik Pharmaceuticals. He previously served on the Board of Directors for Apexian Pharmaceuticals, Cornerstone Pharmaceuticals and PCAsso Diagnostics, LLC, and was Co-Chair of the BioNJ Personalized Medicine & Diagnostics Committee Council (CMOC), the Ontario Institute of Cancer Research Commercial Committee (OICR) and the Pharmaceutical Industry Board of the American Pediatric Family Foundation.

Steve received a B.S. in Marketing from West Chester University and an MBA in Marketing from Drexel University. Steve is a member of the Board of Directors of Sunesis Pharmaceuticals and BioNumerik Pharmaceuticals.


Henrik Moltke

Henrik Moltke

Chief Financial Officer & Board Member

Henrik brings more than 30 years of experience in CFO and Senior Vice President roles within the life sciences and health care sectors, and joined our executive team in 2019. He has been with Oncology Venture since October 2019.

The primary focus in his career has been in venture financing, including IPOs as well as follow on capital increases in the public markets, investor relations, finance, project management, and strategic development.

Henrik has formerly served in such senior roles with companies like Scandinavian Micro Biodevices ApS, Astion Pharma A/S, NeuroSearch A/S, Novo A/S, and Ferrosan A/S.  He has also a broad financial and managerial experience from several listed and unlisted companies as member of their Boards of Directors.

Henrik holds a Masters Degree in international economics and strategic management from Copenhagen Business School, Denmark. Henrik is a member of the Board of Directors of Initiator Pharma A/S and Hartmanns A/S.


James G. Cullem

Senior Vice President,  Corporate Development & Board Member

James is an experienced biotechnology executive, and has been part of our senior team since 2014. He is a Co-Founder of 2X Oncology, Inc. (now Oncology Venture U.S., Inc.).

He brings 20+ years of diverse experience in life sciences organizational management, business development & licensing, intellectual property & technology transfer/commercialization, partnership creation/management, and strategic planning as a member of executive teams.

During his tenure with Oncology Venture, James has been responsible for the identification and acquisition of most of our lead clinical oncology assets, including big pharma therapeutics Dovitinib (from Novartis) and 2X-121 (from Eisai). He has also spearheaded our potential reverse merger discussions, as well as clinical program out-licensing, partnership, and joint venture discussions, both in the U.S. and in major foreign oncology markets.

James has previously designed and negotiated a broad span of life science deals, has founded and lead several early-stage biotech companies, and is a catalyst for businesses taking the next step in the fields of precision medicine and predictive/companion diagnostics, novel drug targets, proteomics and genomics, and clinical-stage cancer therapeutic development.

He holds a B.S. degree in Biochemistry, a juris doctorate (J.D.) degree specializing in patent & I.P. law, and has registered patent attorney status.